Telomir Pharmaceuticals Inc. has announced promising preclinical results from its ongoing development of Telomir-1, an investigational oral small molecule candidate for treating age-related macular degeneration $(AMD)$. The study utilized the Sen57wrn-/-ND6-/+ zebrafish model, which reflects key features of dry AMD and geographic atrophy observed in humans. Over a 14-day period, Telomir-1 was administered orally to 18-month-old animals. The treatment resulted in improved central vision response and motion detection, regeneration of several critical retinal layers, and a reduction in oxidative stress. Notably, untreated animals experienced a 15% mortality rate, while no mortality was observed in the Telomir-1 treated groups. These findings are considered a significant preclinical milestone that supports the continued advancement of Telomir-1 towards an Investigational New Drug $(IND.AU)$ submission.